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ABSTRACT 
 
Cytochrome P450 2W1 (CYP2W1) belongs to a family of drug metabolizing monooxygenases 
with an unidentified yet endogenous function. CYP2W1 expression pattern has characteristic 
features of oncofetal genes. Previous studies have shown significant levels of CYP2W1 
protein in 30% of human colon cancers and in 50% of corresponding liver metastases. High 
expression of CYP2W1 is an independent prognostic factor for poor survival outcomes in 
colorectal cancer (CRC) patients. Such tumor specific feature renders CYP2W1 an attractive 
target for colon cancer therapy. Indeed, CYP2W1-mediated activation of a number of 
duocarmycin related chloromethylindolines demonstrated strong and selective cytotoxic 
effects toward cancer cells in vitro and in vivo. 
 
CYP2W1 is a polymorphic gene. The most frequent genetic variants, are CYP2W1*2 and 
CYP2W1*6 that carry missense mutations producing amino acid changes that might affect the 
enzyme function. A recent study suggested that CYP2W1*2 variant is associated with 
decreased risk of colon cancer. We have analyzed a 10-fold larger patient cohort where no 
such differences in the distribution of CYP2W1*2 and CYP2W1*6 between CRC patients and 
healthy controls could be detected. Moreover, the functional analysis of these enzyme 
variants demonstrated equally potent capacity to metabolize the chloromethylindoline 
substrates. 
 
CYP2W1 enzyme is glycosylated at Asn177 in cancer tissues and in transfected cells, 
suggesting that in contrast to other P450s it has an inverted endoplasmic reticulum (ER) 
membrane topology with the bulk of the protein facing the lumen. We now confirmed such 
membrane orientation based on a number of assays using FLAG-tagged CYP2W1 and also 
CYP2W1 fused with a redox sensitive luciferase reporter that displays full activity only upon 
its oxidative folding in the ER. Such ER topology apparently should hinder CYP2W1 
interaction with its canonical cytosol oriented redox partners, cytochrome P450 reductase 
(POR) and/or cytochrome b5 reductase. This was confirmed by unaffected functional activity 
of CYP2W1 under the conditions of knocked down/inhibited POR and cytochrome b5 
reductase. Interestingly, the nonglycosylated Asn177Ala mutant displayed significantly 
decreased catalytic activity. This study strongly supports the atypical membrane topology of 
CYP2W1 and suggests the interaction of CYP2W1 with a hypothetical ER luminal electron 
donor. 
 
CYP2W1 is transiently expressed during gut development. We described a developmental 
expression profile of CYP2W1 in murine and human gastrointestinal tissues. The gene 
expression is initiated at the early stages of gestation and is completely silenced shortly after 
birth. Such fetal specific expression was shown to be epigenetically regulated and indicates 
possible endogenous role in gut development. Cyp2w1 knock out (KO) mouse model was 
established in order to investigate such possibility. Phenotype analysis revealed decreased 
crypt length in the distal colon epithelium of adult Cyp2w1 KO mice whereas the 
transcriptomic profiling identified a number of genes being down-regulated. The most 
affected genes were found to be involved in the cell adhesion and extracellular matrix 
establishment. 
 
In conclusion, we have characterized polymorphic variants of CYP2W1 and found no 
significant correlation between their distribution and CRC risk. The completely inverted 
membrane topology of catalytically active CYP2W1 suggests its interaction with redox 
partner yet to be identified in the ER lumen. The explicitly developmental pattern of 
expression, the phenotypic and gene expression changes in Cyp2w1 KO gut tissues indicate a 
potential role of CYP2W1 in gut development. 
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1 INTRODUCTION 
 
 
1.1 Cytochrome P450 Superfamily 
 
1.1.1 Function 
 
The name of Cytochrome P450 (CYP, or P450) originates from several decades ago 
when Tsuneo Omura and Ryo Sato in 1962 described a hemoprotein nature of liver 
microsomal pigment as “P-450”: it has a unique character of maximal spectral 
absorbance at 450 nm when the reduced form binds carbon monoxide (Omura and Sato, 
1962). Since then the literature on cytochrome P450 research has expanded 
significantly. 57 CYP genes and 58 pseudogenes have been identified in the human 
genome (Nelson et al., 2004, Ingelman-Sundberg, 2005). The P450 superfamily is 
divided into families and subfamilies which are grouped by their primary structure 
similarity: the ones with > 40% amino acid sequence identity belong to one family, and 
the ones with > 55% identity are sorted into one subfamily (Nelson, 2006). 
Evolution 
Cytochrome P450s are ubiquitously expressed in various species spanning from 
Bacteria, Archaea to Eukarya. It is postulated that the first cytochrome P450 gene 
arose about 3.5 billion years ago when the oxygen-rich atmosphere was not yet in 
place, and acted as nitroreductase. Years of evolution expanded the CYP family 
which plays critical roles in the proper functioning of organisms. The first expansion 
gave rise to CYP11 and CYP4 families which are designated for metabolism of 
endogenous cholesterol, fatty acids that are essential to maintain the membrane 
integrity of early eukaryotic cells. Another expansion of the CYP family brought 
about CYP19, CYP21 and CYP27 families which are involved in the synthesis of 
endogenous steroids. Later expansions further enriched the CYP superfamily with 
CYP1-3 family members that are capable of metabolizing xenobiotics including 
environmental toxicants, procarcinogens and drugs, as well as endogenous substrates 
(Danielson, 2002, Lewis et al., 1998).  
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Enzyme catalysis 
CYP is a superfamily of heme-containing monoxygenases that catalyze the introduction 
of one oxygen atom into the substrates, whereas the other oxygen atom is reduced to a 
water molecule: RH + O2 + 2H
+
 + 2 e
-
               ROH + H2O (Meunier et al., 2004). 
In eukaryotic cells CYPs are anchored to the endoplasmic reticulum (ER) or inner 
mitochondrial membrane (IMM) by the N-terminal hydrophobic signal peptide, 
keeping the majority of enzyme including the bulk of catalytic domain and redox 
interactive domain in the cytosol (type III ER membrane protein, as described below in 
the membrane protein topology section) or mitochondrial lumen (Black, 1992). Such 
topological orientation facilitates electron transfer from their redox partners, 
cytochrome P450 reductase (POR), cytochrome b5 in ER or adrenodoxin (Fdx1) in 
mitochondria (Porter, 2002, Ewen et al., 2011, Hannemann et al., 2007).  
Redox cofactor NAD(P)
+
/NAD(P)H    
NADH and NADPH are the major electron carriers in P450 mediated catalytic cycle. 
They are produced mostly in the cytosol in various metabolic reactions. The cytosolic 
NADPH is generated during the pentose phosphate pathway (PPP) by glucose-6-
phosphate dehydrogenase (G6PDH) and 6-phosphogluconate dehydrogenase 
(6PGDH) using NADP
+
 as an electron acceptor (Lunt and Vander Heiden, 2011, 
Pollak et al., 2007). The cytosolic NADPH/NADP
+
 pool is overall in reduced state, 
maintaining the antioxidant milieu. In addition, a fraction of NADPH/NADP
+ 
exists 
also in the ER lumen. Since the ER membrane is scarcely permeable to pyridine 
nucleotides, the luminal NADPH is produced separately by hexose-6-phosphate 
dehydrogenase (H6PD) and the 11 beta-hydroxysteroid dehydrogenase type 1 (11ß-
HSD1) is one of the major NADPH consuming enzymes. These enzymes work in 
tight connection to sustain the luminal NADPH homeostasis (Csala et al., 2006, 
Banhegyi et al., 2004, Czegle et al., 2006, Banhegyi et al., 2012).  
 
1.1.2 Structure and substrate binding 
 
Mammalian CYPs can be divided into two groups according to their substrate binding 
specificity: one group with narrow substrate specificity, which is mostly involved in the 
biosynthesis, activation or inactivation of endogenous regulatory molecules; the other 
group shows very broad substrate binding spectrum, representing the xenobiotic 
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metabolizing P450s. 
 
The three dimensional (3D) structure analysis of cytochrome P450 can provide the 
molecular perspective of substrate recognition and binding sites. The microbial P450s 
are fully soluble proteins while mammalian P450s are membrane bound. Despite only 
20-30% of amino acid identity between prokaryotic and eukaryotic P450s, the overall 
fold was predicted to be conserved, which is why the structure-function studies of 
mammalian P450s were previously based on the bacterial P450 structural model (e.g. 
CYP101/ Cytochrome P450cam) (Li and Poulos, 1996, Schlichting et al., 1997, Li and 
Poulos, 1997, Podust et al., 2001). The obstacle for the determination of the crystal 
structure of mammalian P450s is the hydrophobic amino-terminal hydrophobic 
fragment. Therefore, in 2000, the first structure of membrane-associated P450, the 
rabbit CYP2C5 was solved by truncating of the N-terminal transmembrane helix and 
modulating the solubility of the second superficial membrane-binding region (Williams 
et al., 2000, Cosme and Johnson, 2000). Since then, the 3D structures of a few other 
mammalian P450s have been published including rabbit CYP2B4 and human CYP2C8, 
CYP2C9, CYP3A4, CYP2D6, CYP2A6 and CYP1A2, etc. (Scott et al., 2003, 
Williams et al., 2003, Schoch et al., 2004, Williams et al., 2004, Rowland et al., 2006, 
Yano et al., 2005, Sansen et al., 2007). The advancement of the X-ray crystallography 
of the substrate-bound proteins allowed the establishment of the substrate recognition 
site (SRS) map of CYPs, which made possible prediction of the substrate-binding 
residues. There are six putative SRS regions in eukaryotic P450s that are scattered 
along the primary structure and account for 16% of the total amino acid residues 
(Zawaira et al., 2011, Gotoh, 1992). 
 
1.1.3 Extrahepatic P450s 
 
CYPs are mostly expressed in the liver, and are responsible for the biotransformation of 
clinically administrated drugs, other xenobiotics (e.g. alcohol, procarcinogens) and 
endogenous compounds into easily excreted, hydrophilic metabolites. A number of 
CYPs is detected also in extrahepatic tissues and organs, including brain, heart, kidney, 
adrenal, thymus, etc., which could be important in regulating the metabolism of 
xenobiotics and/or endogenous substrates at the local sites (Karlgren et al., 2005).  
Many CYPs are found in respiratory and gastrointestinal (GI) tracts, the entry sites of 
the xenobiotics into the human body, e.g. lung, nasal tissue, small intestine, colon, etc. 
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A very detailed summary of the expression and regulation of extrahepatic CYPs in 
these tissues can be found in the review by Ding and Kaminsky, 2003 (Ding and 
Kaminsky, 2003).  
 
Most of the CYPs identified in extrahepatic tissues are still mainly expressed in the 
liver, however, there are several CYPs that are preferentially expressed in extrahepatic 
tissues, which can lead to a tissue-specific metabolism profile of xenobiotics or 
endogenous substances. For instance, the CYP2S1 enzyme is highly expressed in 
human skin, small intestine, kidney with low expression level in the liver. Researchers 
found that there are significant individual variations in CYP2S1 cutaneous expression 
levels and it can be induced by ultraviolet radiation and all-trans retinoic acid. This 
implies that the topical drugs can be metabolized at different rates (Smith et al., 2003, 
Saarikoski et al., 2005)  
 
The CYPs from family 1-3 that are expressed in gastrointestinal tract account for a part 
of the first-pass effect of orally administered drugs (Doherty and Charman, 2002). 
CYP3A4 is the most pronounced P450s in small intestine, other well documented GI 
CYPs include CYP1A1, CYP2C9, CYP2C19, CYP2J2, CYP2D6 (Paine et al., 2006, 
Kaminsky and Zhang, 2003). Clinical studies showed that a few drugs, e.g. midazolam, 
nifedipine, tacrolimus are mostly metabolized in the intestinal mucosa. Besides the 
CYP1-3 enzymes, there are also other CYPs in the GI tract, which are involved in the 
metabolism of endogenous substrates, such as CYP4 enzymes, CYP24A1 (1,25-
dihydroxyvitamin D3 24-hydroxylase), CYP26A1, CYP27B1 (25 hydroxyvitamin D3-
1-alpha hydroxylase) etc. (Kumarakulasingham et al., 2005, Anderson et al., 2006). 
Within the GI tissues, most CYPs are expressed in the intestinal epithelial cells, such as 
enterocytes or goblet cells, the very front line that interacts with xenobiotics. Other GI 
tissues also show CYPs expression: CYP1B1 is found in blood vessel walls and high 
levels of CYP2J2 are detected in autonomic ganglia, intestinal smooth muscle cells and 
vascular endothelium (Gibson et al., 2003, Zeldin et al., 1997). 
 
1.1.4 P450 Polymorphism and precision medicine 
 
On January 20, 2015 U.S. president Obama announced the Precision Medicine 
Initiative (PMI), ushering in a new era of individualized medical care that takes into 
account the interindividual variations in genes, environment and lifestyles for disease 
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prevention and treatment. Pharmacogenetics investigates polymorphic changes in the 
drug metabolizing genes causing interindividual variations in the drug response. 
 
Cytochrome P450s are responsible for the Phase I metabolism (oxidation) of 70% 
clinically prescribed drugs directly determining the efficacy and turnover rate of the 
drugs by their inactivation or activation of the prodrugs. Despite of their importance, 
P450 genes exhibit high variability among individuals. The genetic variations include 
single nucleotide polymorphism (SNP), copy number variation (CNV), insertions and 
deletions. The nonsynonymous SNPs usually cause amino acid substitutions while 
CNV may alter gene expression level, which ultimately affect the enzyme catalytic 
activity and the pharmacokinetic property of relevant drugs.  
 
The major polymorphic CYPs are from CYP2 family including CYP2A6, CYP2B6, 
CYP2C9, CYP2C19 and CYP2D6, as well as CYP3A5, which have been intensively 
studied and well characterized (Ingelman-Sundberg, 2004). Less has been reported on 
polymorphisms in CYP1A1, CYP1A2, CYP2C8, CYP2E1, CYP2J2, and CYP3A4. 
Polymorphisms in P450 redox partners such as cytochrome P450 reductase can also 
affect CYP enzyme function and catalytic activity (Hart and Zhong, 2008). The 
combinations of allelic variants result in different phenotypes which are known as poor, 
intermediate, extensive, and ultrarapid metabolizers (Ingelman-Sundberg et al., 2007).  
 
Cancer chemotherapy is very unspecific and has narrow therapeutic window, which can 
cause severe or even fatal toxicity. However, lack of therapeutic effect due to excessive 
metabolism is also unwanted. Cytochrome P450s are responsible for the activation or 
inactivation of many anti-cancer drugs. One example is the highly polymorphic 
CYP2D6 mediating activation of tamoxifen, an estrogen receptor modulator used for 
prevention and treatment of breast cancer. Considering the high degree of genetic 
polymorphisms of these isoforms that can result in the altered catalytic activities and 
ultimately affect the drug efficacy, it’s imperative to perform genotyping for the 
prediction of catalytic activity of the enzyme and thus make possible the personalized 
treatment (Rodriguez-Antona and Ingelman-Sundberg, 2006, Ruddy et al., 2013)  
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1.2 Cytochrome P450 2W1 
 
CYP2W1 is one of the latest members in cytochrome P450 superfamily, which is so far 
an orphan enzyme with undefined function. The first partial sequence of human 
CYP2W1 gene was identified in a cDNA library from human hepatoma cell line HepG2 
in 2000 and later the full length cDNA was cloned (Karlgren et al., 2006). The 
CYP2W1 gene is evolutionarily conserved. The human CYP2W1 gene is located on 
chromosome 7, consists of 9 exons, and has the highest sequence identity with other 
two CYP2 family members, CYP2D6 and CYP2S1. A number of publications 
illuminated various aspects of this enzyme including its expression profile, specific 
substrates, regulation, polymorphisms and its potential role in colon cancer therapy. 
 
1.2.1 Oncofetal expression 
 
Among various extrahepatic CYP enzymes, CYP2W1 has shown a unique oncofetal 
expression pattern. Significant amounts of CYP2W1 transcript are identified in the fetal 
rat colon tissues (Karlgren et al., 2006), however the enzyme was not found in any 
adult tissue. Choudhary et al showed that Cyp2w1 is transcribed in pooled fetal mouse 
tissue (Choudhary et al., 2005). A detailed developmental curve of CYP2W1 
expression in human and mouse colon and intestine is presented in paper II. 
The scanning of the RNA panel of multiple human tumor tissues revealed that 
significant amount of CYP2W1 mRNA is present in human colon tumor tissues, and to 
a lesser extent in the adrenal gland tumors. However the CYP2W1 expression is absent 
in any of examined normal tissues using multiple tissue expression array and multiple 
tissue northern blot, indicating a tumor specific expression pattern (Karlgren et al., 
2006). With the development of the CYP2W1 specific antibody, several studies 
provided with the solid evidence of high CYP2W1 protein expression in colon tumors 
(Gomez et al., 2007, Edler et al., 2009, Stenstedt et al., 2014, Stenstedt et al., 2012). In 
addition, CYP2W1 tumor expression profiles have been expanded by a flood of recent 
publications which show various levels of CYP2W1 expression in breast cancer 
(Bandala et al., 2012), childhood rhabdomyosarcoma (Molina-Ortiz et al., 2014), 
hepatocellular carcinoma (Zhang et al., 2014), adrenocortical carcinoma (Ronchi et al., 
2014), oral squamous cell carcinoma (Hartanto et al., 2015). Due to the limited 
specificity of commercial CYP2W1 antibodies, further validations are needed for most 
of these cancer types. Moreover, high levels of the enzyme are also detected in several 
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cancer derived cell lines including the hepatoma cell line HepG2, colorectal carcinoma 
cell lines Caco2-TC7, HCC2998 and KM12, breast cancer cell line MCF7 (Tan et al., 
2011). 
 
1.2.2 Prognostic factor for CRC and potential role in targeted therapy   
 
Two clinical studies have analyzed CYP2W1 expression in colorectal cancer patients 
and sought for potential correlation between the enzyme level and cancer malignancy. 
In the first cohort, 162 tumors from patients with stages II and III colorectal cancer 
(CRC) were analyzed. Among them, 64% of tumors displayed significant CYP2W1 
levels as revealed by immunohistochemistry detection while the signal from the nascent 
normal tissues was negligible, and 36% showed very intensive staining. The high 
expression of CYP2W1 is associated with worse clinical outcome of overall survival 
rate, which is an independent prognostic factor in multivariate analysis (p=0.04) (Edler 
et al., 2009). Another independent cohort consisted of 235 malignant colon tumors 
from stage II and III CRC patients to exam CYP2W1 expression. In line with the 
previous study, high level of CYP2W1 was detected in 30% of the tumors. CYP2W1 
expression is an independent prognostic factor in the patients with stage III colorectal 
cancer (p=0.003) (Stenstedt et al., 2012). A follow-up study on primary colorectal 
tumors and the corresponding lymph node and liver metastases revealed high CYP2W1 
expression in 50% of metastatic tissues, which promises good perspectives for targeting 
CYP2W1 in metastases (Stenstedt et al., 2014). Recently, Zhang K, et al. suggested the 
prognostic value of CYP2W1 expression in hepatocellular carcinoma (HCC) which is 
based on a cohort study of 133 HCC patients (Zhang et al., 2014). 
Tumor specific expression of CYP2W1 offers attractive opportunities for the 
development of targeted cancer therapy. A library of duocarmycin derivatives that can 
be converted into cytotoxic metabolites by CYP2W1 was developed at the University 
of Bradford, UK (Sheldrake et al., 2013). The inactive chloromethylindoline 
duocarmycin analogues undergo hydroxylation followed by spirocyclization to form 
the cyclopropane ring, thus becoming potent DNA-alkylating agents and being able to 
induce DNA replication stalling and cell death. Among them, ICT2705 and ICT2706 
emerged to exhibit very high affinity towards CYP2W1 in the stably transfected cell 
lines and showed potent cytotoxicity while the mock cells without CYP2W1 expression 
remained intact. Further, ICT2706 was tested in vivo in a xenograft mouse model of 
colon cancer. As shown in Figure 1, the results demonstrated significant tumor growth 
 8 
inhibitory effect of ICT2706 in a CYP2W1 dependent manner. Moreover, such 
cytotoxicity can be propagated by the bystander effect to the surrounding cells in close 
proximity through the transfer of the active metabolite.  Pharmacokinetics analysis of 
tumor and plasma concentrations after the administration of ICT2706 showed the 
accumulation of the compound preferentially in tumor tissues. Taken together, these 
studies suggest a possibility of a novel colon cancer therapy based on the CYP2W1 
bioactivation of anticancer prodrug at local sites (Travica et al., 2013). Moreover, a 
non-toxic chloromethylindoline CYP2W1 substrate ICT2726 was suggested as a probe 
to detect the enzyme activity prior to the therapy.    
 
Figure 1.  ICT2706 inhibits tumor growth in the mouse xenograft model of human 
colon cancer. Left: Tumors with CYP2W1 expression (SW480-2W1); right: Tumors 
without CYP2W1 expression (SW480-mock). Adapted from (Travica et al., 2013). 
 
1.2.3 Substrate specificity  
 
Although being grouped into the CYP2 family, CYP2W1 demonstrates the most 
similarity in substrate binding with the CYP1 family member, CYP1A1, which is in 
line with the substrate recognition site (SRS) prediction (Karlgren and Ingelman-
Sundberg, 2007). Efforts have been made to demonstrate catalytic capability of 
CYP2W1 towards various substrates. Most studies were carried out in reconstituted 
systems with the E. coli expressed N-terminally truncated human CYP2W1 and 
NADPH or NADPH regenerating system (Mazur et al., 2009). The putative CYP2W1 
substrates can be categorized briefly into three types: I. procarcinogens; II. anti-tumor 
drugs; III. endogenous compounds.  
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The reported procarcinogens include aromatic amines, polycyclic aromatic 
hydrocarbon dihydrodiols, sterigmatocystin, which have relatively low turnover rates 
by CYP2W1 (Wu et al., 2006, Eun et al., 2010). The anti-tumor drugs, such as AQ4N, 
GW610, 5F203 (Wang and Guengerich, 2012, Tan et al., 2011) have also shown to be 
substrates of CYP2W1. However, the 5F203 is predominantly metabolized by 
CYP1A1, whereas fluorobenzothiazole GW610 shows more specificity towards 
CYP2W1. Low metabolism rates have been shown in CYP2W1 mediated 
benzphetamine demethylation, and indole oxidation (Wu et al., 2006, Yoshioka et al., 
2006). Meanwhile, a series of putative endogenous substrates was suggested for 
CYP2W1. A systematic study has been carried out by Xiao Y and Guengerich FP 
where the colorectal tumor extracts were incubated with purified recombinant 
CYP2W1 enzyme. The metabolites were analyzed by LC-MS. The results showed that 
CYP2W1 catalyzes selective hydroxylation or epoxidation of lysophospholipids, 
lysophosphatidylcholines (LPC) in particular and free fatty acids (FFA) (Xiao and 
Guengerich, 2012). Another recent study showed that CYP2W1 has tight binding 
constants for retinoids including all-trans retinol, all-trans retinal and all-trans retinoic 
acids at nanomolar level (Zhao et al., 2016b). This is, so far, the highest affinity 
reported for any CYP2W1 substrates. Considering the important signaling function of 
retinoids in cell proliferation, differentiation and carcinogenesis, it was suggested that 
CYP2W1 might play a role in tumor development via mediating retinoids metabolism. 
The study also reported less efficient metabolism towards 17 ß-estradiol, farnesol, 
arachidonic acid. However, these experiments were accomplished under anaerobic 
conditions, which necessitates confirmation in vitro (cell system) and in vivo.  
 
Stable expression of CYP2W1 in mammalian cells provides a useful tool to explore its 
specific substrates under physiological situations. The CYP2W1 transfected HEK293 
cells reveal catalytic activity towards indolines and aflatoxin B1 (Gomez et al., 2010) 
which paved the road for later development of the chloromethylindoline duocarmycin 
analogues as described above. The nontoxic substrate ICT2726 has a Km value of 
3.46±1.17 µM in the CYP2W1 transfected SW480 cells (Stenstedt et al., 2013). 
 
1.2.4 Regulation 
 
It is well established that the expression of many cytochrome P450 genes are regulated 
by nuclear receptors such as pregnane X receptor (PXR), constitutive androstane 
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receptor (CAR), aryl hydrocarbon receptor (AhR) on transcriptional level. However, 
the extrahepatic CYP2W1 has a unique oncofetal expression pattern, which suggests 
possible involvement of epigenetic regulation. Initial study has shown that the 
treatment by demethylation reagent AzaC triggers the re-expression of the enzyme in 
human hepatoma cell line B16A2 that previously had no detectable CYP2W1, implying 
the significant role of epigenetic modification (Karlgren et al., 2006). Indeed, a CpG 
island was identified in the exon1-intron 1 junction of CYP2W1 gene. An elegant study 
has shown that the methylation level of this locus in CYP2W1 gene reversely correlates 
with its expression when comparing colon tumor tissue to the corresponding normal 
tissue (Gomez et al., 2007). DNA methylation thus represents the primary, if not the 
only, mechanism that explains the tumor specific expression of CYP2W1. Studies 
presented in paper II further demonstrate the role of epigenetic modification in 
determining the transient fetal expression of CYP2W1 in both human and mice gut 
tissues. It is also shown that CYP2W1 expression could be induced by anti-tumor 
reagents e.g. GW610, imatinib in several carcinoma cell lines (Tan et al., 2011), (paper 
II), suggesting the involvement of undefined tissue specific transcriptional regulators. 
However, PXR agonist rifampicin and AhR agonist TCDD are unable to enhance 
CYP2W1 expression (presented in paper II) which exclude their participation in 
modulating CYP2W1 transcription.    
 
1.2.5 Polymorphism 
 
The members of CYP2 family e.g. CYP2C9, CYP2C19, CYP2D6 are known for their 
high frequency of polymorphism. Not surprisingly, several single nucleotide 
polymorphisms (SNP) have been described in CYP2W1 gene too. A study covering all 
nine exons and exon-intron junctions on Japanese population reported six 
nonsynonymous SNPs which lie in the exon 1, 4 and 9. In haplotype analysis, the 
allelic variants are characterized (CYP2W1*2-*6) with CYP2W1*1 as the reference 
(Hanzawa et al., 2008). Among them, CYP2W1*6 displays the most significant 
frequency with amino acid substitution Pro488Leu. Ten novel SNPs have been 
described recently in Chinese Uygur and Han populations with seven SNPs in the 
exons and the other three in the introns. Four novel non-synonymous polymorphisms 
producing amino acid substitutions might affect CYP2W1 function. The allelic 
frequencies are different among Chinese Han, Uygur and Caucasians, e.g. 2.9%, 5.2%, 
9.1% for CYP2W1*2 and 0%, 0%, 33.1% for CYP2W1*3 (Qi et al., 2015).  
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Considering the prognostic value of CYP2W1 in colon cancer, it was postulated that 
CYP2W1 alleles might be associated with increased or decreased cancer risk. Gervasini 
G et al. investigated the frequency differences of nonsynonymous SNPs in CYP2W1 
gene between CRC patients and healthy subjects and the result suggested that 
CYP2W1*2 (Ala181Thr) is associated with lower risk for CRC (Gervasini et al., 2010). 
In Paper I, a thorough study based on a much larger cohort has been carried out in order 
to illuminate the relationship between CYP2W1 genotype and colon cancer risk as well 
as the catalytic function of the enzyme variants.  
 
1.2.6 Posttranslational modification 
 
Western blot detection of CYP2W1 in the transfected cells and cancer tissues 
consistently reveals two immunoreactive bands (52 and 54 kDa), indicating that 
CYP2W1 might be subject to posttranslational modification (Aguiar et al., 2005, 
Gomez et al., 2010). In silico analysis by the NetNGlyc software predicted possible N-
glycosylation at Asn177 site. Site-directed mutation of Asn177 residue resulted in the 
disappearance of the upper band (54 kDa) which confirmed the glycosylation of 
CYP2W1 enzyme. Moreover, a migration shift from 54 kDa to 52 kDa of the CYP2W1 
immunoreacitve bands was observed when the microsomal fractions from transfected 
cells or colon tumors were treated with deglycosylating enzymes, EndoH and PNGase 
(Gomez et al., 2010). Cytochrome P450s have typical cytosolic orientation, thus 
making them inaccessible to the ER luminal residing glycosylation machinery. In order 
to solve this puzzle, it is critical to determine the membrane topology of CYP2W1. 
Protease protection assay suggested that CYP2W1 may have an inverted topology with 
the majority of the molecule orienting towards ER lumen, thus enabling the 
glycosylation process. It was previously reported that a small fraction of CYP enzymes 
are inversely anchored to the ER membrane and can be further directed to the plasma 
membrane (Neve and Ingelman-Sundberg, 2010, Neve and Ingelman-Sundberg, 2000). 
Indeed, 8.1% of total CYP2W1 is localized on the cell surface of transfected HEK293 
cells as detected by biotinylation assay (Gomez et al., 2010). However, given the fact 
that the canonical P450 reductases (POR, cytochrome b5 reductase) are oriented toward 
cytosol, one would wonder how CYP2W1 obtains electrons having such an atypical 
orientation. Investigation regarding the membrane topology and search for potential 
redox partner of CYP2W1 is illustrated in paper III. 
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Figure 2. The electron transfer chain to typical CYPs (e.g. CYP2C8) and the 
posttranslational modification and atypical orientation of CYP2W1. CYB5R: 
cytochrome b5 reductase; Cyt b5: cytochrome b5; POR: P450 reductase. 
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1.3 Membrane Protein Topology 
 
1.3.1 Membrane topology 
 
The definition of membrane topology is “a specification of the number of 
transmembrane helices and their in and/or out orientations across the membrane in a 
membrane protein.” (von Heijne, 2006). Topology has its great importance in 
determining the fully folded three dimensional (3D) structures of membrane proteins 
from the amino-acid sequence. With recent development in the field of X-ray 
crystallography, databases have expanded by exponentially increasing numbers of 
high-resolution 3D structures of membrane proteins, which enrich the concept of 
topology with deeper understanding and more complex interpretation. For instance, 
the membrane-embedded helices can be so various: they could cross the membrane 
by oblique angles or just lie flat on the membrane surface, or form the “re-entrant” 
loops by spanning only a part of membrane and turning back. Moreover, if one 
considers how to define the transmembrane helix, it’s not clear how far exactly the 
helix should reach the interface regions on both sides of the membrane to be qualified 
(von Heijne, 2006). Nevertheless, we hereby discuss the single spanning membrane 
protein topology adopting the less complicated definition. 
 
1.3.2 Protein translocation and targeting to endoplasmic reticulum 
 
The proteins are translated from messenger RNAs on cytosolic ribosomes and are 
targeted to their corresponding subcellular locations. Generally, the incorporation of 
proteins into endoplasmic reticulum (ER) membrane are directed by certain signals 
which are characterized as uncharged, predominantly hydrophobic N-terminal 
sequences of 7-25 amino acids. The membrane proteins that are tethered to ER can be 
divided into three groups, according to their ways of inserting the single or multiple-
spanning transmembrane helixes into the ER membrane. The type I membrane 
proteins initiate the translocation by their C-terminal sequence; the cleavable signal at 
N-terminus is cleaved off by signal peptidase and new luminal N’-terminus is 
generated; type II membrane proteins have similar translocation pattern at their C-
terminus, however the N-terminus remains uncleaved and span the hydrophobic core 
of the bilayer with an Ncyt/Clum orientation (N-terminus in cytosol, C-terminus in ER 
lumen); type III or often classified as type Ia, induce the translocation of the N-
terminus with reverse signal anchors, resulting in an Nlum/Ccyt orientation (Higy et al., 
 14 
2004). A typical example of type III ER membrane protein is cytochrome P450 
enzyme. 
 
Figure 3.  The three types of ER membrane protein, adapted from (Higy et al., 2004). 
Type I and type II proteins have the signal-anchor sequences (red) that induce the 
translocation of the C-terminus and assume an Ncyt/Clum orientation. The arrowhead 
indicates cleavable signal. Type III protein has reverse signal anchor (blue) that 
translocates the N-terminus and inserts with an opposite Nlum/Ccyt orientation. Grey 
bar: additional transmembrane segment. 
 
1.3.3 Methods for membrane topology determination 
 
The primary role of the membrane in cells is to separate different organelles from the 
cellular matrix and ensure the individual compartments function well in their specific 
roles. For instance, endoplasmic reticulum, as the protein processing machinery for 
proper folding, employs the membrane to maintain a relatively oxidative environment 
in the lumen in order to facilitate the protein disulfide bond formation. In contrary, on 
the other side of the membrane, the cytoplasm has a rather reductive environment. 
Therefore, the orientation of the membrane protein and its specific topology underlies 
the correct functionality as it determines the accessibility of the protein to its 
cofactors or substrates within certain microenvironment.  
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Given the important role of topology for protein function, different approaches are 
developed in order to probe the topological distribution.  
Computational predictions. A number of web-based in silico prediction approaches 
have been developed over the last decades (OCTOPUS, SCAMPI-single, SCAMPI-
multi, TOPCONS, Tmpred, etc.), providing immediate and fundamental structural 
information of the transmembrane proteins, e.g. examination of the relative 
hydrophobicity of different peptide regions of a protein to predict membrane-
spanning domains. Considering the difficulties in obtaining the structural knowledge 
experimentally for transmembrane proteins, computational methods are of 
exceptional significance. However, the prediction results of such methods are, as 
expected, not solid, and different prediction methods often give inconsistent outcomes 
that are based on different algorithms, leading to uncertain result (Bernsel et al., 
2009). Neither can they provide detailed information regarding to whether the N- or 
C- terminus faces the cytosol, lumen or cell exterior. 
Engineering epitope is another category of approaches for characterizing the 
topological distribution. Epitopes such as hemagglutinin (HA), FLAG and myc, are 
tethered to N- or C- terminus of the protein of interest. Immunoreactivity of the 
epitopes is further analyzed by antibody labelling before and after the 
permeabilization of cellular membrane. Such methods are applied mostly to 
distinguish between extracellular and intracellular orientation. Similar principle is 
adopted by protease protection assay to unravel the more detailed topological 
knowledge at the subcellular organelle level (Jarvik and Telmer, 1998).  
Fluorescence protease protection (FPP) is a recently developed assay to determine 
the membrane protein topology in living cells (Lorenz et al., 2006). Briefly, a 
fluorescent protein is attached to the N- or C-terminus of the questioned protein. Cells 
expressing the fusion protein are treated with trypsin before or after the exposure to 
low concentration digitonin, which can efficiently permeabilize the plasma membrane 
while keeping the intracellular membranes intact. The plasma membrane proteins 
facing the cell exterior would be the very first to be digested by trypsin, as 
extracellular trypsin is inaccessible to the interior of intact cells. Meanwhile, the loss 
of fluorescence signal when digitonin is added indicates that the fluorescently tagged 
protein faces cytoplasm. Conversely, if the fluorescence signal is not affected when 
exposed to trypsin and digitonin, it indicates a luminal orientation of the protein of 
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interest in subcellular organelles, e.g. ER, Golgi apparatus, mitochondria or 
peroxisomes.  
Redox-sensitive luciferase assay provides with a powerful tool to characterize the 
localization and topology of endoplasmic reticulum proteins. As mentioned above, 
the redox environment in the ER lumen is particularly oxidative compared to 
cytoplasm, which confers the redox sensitive reporter with alternating activity modes 
depending on specific orientation and topology of either single- or multiple-pass 
transmembrane proteins in ER. One of the redox sensitive proteins, Gaussia 
luciferase (Gluc) is isolated from the copepod marine organism Gaussia princep, 
consisting of 185 amino-acid. The proper folding of Gluc, which is possible only in 
the oxidative environment of ER lumen, enables the catalysis of coelenterazine 
oxidation, producing quantitative bioluminescent signal, which is > 10-fold higher 
than in cytosol. The tandem Gluc-GFP (GG), where GFP is used to normalize the 
protein expression level, is designed as a redox sensitive reporter that can be fused to 
different positions of a target protein to determine its topology (Li et al., 2012, 
Tsachaki et al., 2015).  
 
Figure 4. The tandem Gluc-GFP (GG) redox sensitive reporter. Oxidative folding of 
Gluc in the ER lumen produces an active enzyme. 
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1.4 Parallels between Embryogenesis and Carcinogenesis 
 
Embryonic development is featured as a well-regulated process of programmed cell 
proliferation and differentiation in order to shape an organized and “well behaved” 
structure. On the contrary, cancer is a “community” that has the least governance, and 
is notorious for harboring enormous genetic or epigenetic abnormalities. Despite the 
apparent distinctions between embryogenesis and carcinogenesis, there are quite a 
few common cellular and molecular hallmarks between them (Aiello and Stanger, 
2016). 
  
1.4.1 Re-activation of developmental signaling pathways in cancer 
 
Cancer is characterized by re-activation of various embryonic signals in adulthood 
which arise from accumulated genetic mutations and epigenetic abnormality. The 
critical signaling pathways in development including Wnt, Hedgehog (HH) and 
Notch, are frequently dysregulated to a large extent in cancer and are involved in the 
initiation, progression of primary tumor growth and distant metastases in different 
cancer types (Aiello and Stanger, 2016). 
 
In colorectal cancer, the transcriptional recapitulation of a large cluster of embryonic 
genes is demonstrated by comparing the expression pattern of human CRC and 
mouse colon tumor models to those of the embryonic mouse colon during E13.5-18.5 
(Kaiser et al., 2007). The cancer activated genes are functionally associated with cell 
cycle progression, proliferation, and migration. The identification of their normal 
counterparts’ role in embryogenesis would likely provide valuable insights for cancer 
therapeutic strategies (Hu and Shivdasani, 2005, Hendrix et al., 2007). 
 
1.4.2 Examples of oncofetal genes  
 
Carcinoembryonic antigen (CEA) is a group of cell adhesion glycoproteins, 
belonging to the immunoglobulin superfamily. They were identified in 1965 from 
human colon cancer tissue extracts, and are very widely used as biomarkers for 
prognosis and prediction of recurrence after surgical resection. Regarding to ontogeny, 
CEA is produced in gastrointestinal tissues during fetal development, and the 
expression is silenced in adult tissue (Hammarstrom, 1999, Benchimol et al., 1989).  
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SALL4 in hepatocellular carcinoma The SALL4 gene encodes a C2H2 zinc-finger 
transcription factor which is a critical regulator in maintaining the pluripotency and 
self-renewal of embryonic stem cells. The expression of Sall4 in murine liver 
decreases continuously during the development and is undetectable in adult liver, 
indicating its potential role in fetal liver development during early-to-middle stages.  
SALL4 gene is found to be re-expressed in various types of cancers including 
hepatocellular carcinoma, acute myeloid leukemia, lymphoma, breast cancer etc., and 
is essential for cancer cell proliferation, thus defining it as an oncogene (Kobayashi et 
al., 2011, Ma et al., 2006, Cui et al., 2006, Oikawa et al., 2013). Remarkably, the 
study on hepatocellular carcinoma patients reveals 55.6% positivity of SALL4 
expression in tumor samples. Differential expression of SALL4 is observed in 
matched tissue samples with up-regulated levels in neoplastic specimens, and the high 
expression level of SALL4 in hepatocellular carcinoma patients is associated with 
poor prognostic outcome (Yong et al., 2013).  
 
1.4.3 P450s in development 
 
The fetal development of the mammals relies on fine-tuned spatio-temporal 
expression of regulators in various signaling pathways, some of which are synthetized 
or metabolized by CYP enzymes (Rifkind et al., 1995). There is growing evidence for 
the important functions of CYPs during embryogenesis. One example is that the 
complete depletion of cytochrome P450 reductase POR, the primary electron donor 
for microsomal P450s, in mouse leads to multiple developmental defects observed 
early at day 10.5 of gestation, and results in embryonic lethality by embryonic day 
13.5 (E13.5) (Shen et al., 2002). 
 
The first systematic investigation of mouse CYP expression patterns during 
development was done by Choudhary et al. The mRNAs of 40 known mouse Cyp 
genes were quantified from E7 until E17 (Cyp2w1 gene was not included). A number 
of CYP members are constitutively expressed through all developmental stages, 
including Cyp2s1, Cyp8a1, Cyp20, Cyp21a1, Cyp26a1, Cyp46, and Cyp51 
(Choudhary et al., 2003). CYP26 are the major enzymes that metabolize the all-trans 
retinoic acid (RA). Both the Cyp26a1 and Cyp26b1 null mice are lethal at neonatal 
stage (Abu-Abed et al., 2001, Yashiro et al., 2004). Cyp26 enzymes have important 
role in establishing an uneven distribution of RA along the anterio-posterior axis, 
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which is essential for the hindbrain patterning (Sakai et al., 2001). CYP2S1, 
CYP2W1 and CYP1B1 are also reported to metabolize retinoids (Saarikoski et al., 
2005, Zhao et al., 2016a, Choudhary et al., 2004). 
 
Cyp1b1 protein demonstrates a spatio-temporal expression pattern during mouse eye 
ontogeny and plays an important role in the normal eye development (Choudhary et 
al., 2007). Cyp1b1 knockout mice reveals developmental abnormalities of the 
drainage structures of the eye resembling those reported in human primary congenital 
glaucoma (PCG) (Libby et al., 2003). In human, CYP1B1 immunostaining shows 
more intense signal in fetal eyes when compared to adult eyes (Doshi et al., 2006). It 
is well documented that CYP1B1 gene mutation is a common cause of human PCG, 
potential future clinical treatment is proposed for glaucoma patients by delivering the 
wild type CYP1B1 gene to adult stem cells from eye (Choudhary et al., 2009, 
Vasiliou and Gonzalez, 2008).  
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2 AIMS 
 
The overall aim of this thesis was to provide more insights into the genetic 
polymorphism, expression regulation, membrane topology and endogenous function 
of CYP2W1 enzyme. 
 
The specific aims were: 
 
I. Investigation of the association between the CYP2W1 polymorphism and the 
risk of colorectal cancer, evaluation of the catalytic characteristics of 
CYP2W1 variant proteins. 
 
II. Elucidation of the regulatory mechanisms of the fetal expression of CYP2W1 
and search for potential inducers. 
 
III. Characterization of the membrane topology and search for the redox partners 
of CYP2W1. 
 
IV. Investigation of the endogenous function of CYP2W1 in colon development 
by a Cyp2w1 knockout mouse model. 
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3 RESULTS AND DISCUSSION 
 
3.1 CYP2W1 Polymorphism: Functional Aspects and Relation to Risk 
for Colorectal Cancer (Paper I) 
 
In the CYP superfamily genetic polymorphisms are rather prevalent among different 
populations, and the polymorphic gene variants can code for the enzymes that have 
increased or decreased catalytic activity. In the CYP2W1 gene, six single nucleotide 
polymorphisms (SNPs) have been described in a study on Japanese population, which 
are located in the protein coding area causing amino acid changes. The variant alleles 
are designated as CYP2W1*2 to CYP2W1*6, whereas the reference allele is defined as 
CYP2W1*1 (Hanzawa et al., 2008).  
 
A previous study by Gervasini and coworkers suggested that CYP2W1*2 genetic 
variant is associated with decreased risk of colorectal cancer based on clinical analysis 
and genotyping of genomic DNA samples from 150 colorectal cancer (CRC) patients 
and 263 healthy controls (Gervasini et al., 2010). In light of the availability of specific 
and high-affinity duocarmycin analogue substrates for CYP2W1 enzyme, it was of 
interest to study whether the genetic variants code for enzymes that display functional 
differences, and also validate their correlation with CRC risk on significantly larger 
cohort of patients. 
 
In the current study 1785 CRC patients and 1761 healthy blood donors were included 
in order to analyze the distribution of three CYP2W1 allelic variants (CYP2W1*1, 
CYP2W1*2, CYP2W1*6). The molecular epidemiological study revealed, in contrast to 
the previous study, that the allelic frequencies and genotypes of CYP2W1 variants were 
equally distributed between the CRC patients and healthy controls. Therefore, our 
results do not support the decreased risk of CRC among CYP2W1*2 carriers.  
 
We further evaluated the functional aspects of the three variants. In transiently 
transfected colon cancer cells SW480 expressing CYP2W1.1, CYP2W1.2 and 
CYP2W1.6, the expression of each variant was determined to be at the same level by 
western blot. Duocarmycin analogues were used to investigate the catalytic activity of 
the CYP2W1 variants in the transfected cells. The duocarmycin prodrug ICT2706 was 
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incubated with transfected SW480 cells followed by cell viability assay, showing that 
there was no statistically significant difference between the three CYP2W1 enzyme 
variants in mediating the conversion of ICT2706 into cytotoxic products. Similar 
results were obtained when incubating cells with various concentrations of nontoxic 
substrate ICT2726. The enzyme kinetics results as presented in Figure 5 indicate that 
CYP2W1.2 and CYP2W1.6 have comparable catalytic activity as CYP2W1.1 with the 
equal substrate turnover efficiency.  
 
Taken together, our study clarified that there is no significant difference in the 
distribution of three CYP2W1 genetic variants between CRC patients and healthy 
controls. The functional analysis of CYP2W1.1, CYP2W1.2, and CYP2W1.6 revealed 
equal capability in metabolizing duocarmycin analogue substrates. Our study indicates 
that there is no prerequisite of genotyping CYP2W1 when applying the CYP2W1-
targeted precision medicine to CRC patients. 
 
 
Figure 5. The enzyme kinetics of CYP2W1 variants mediated ICT2726 metabolism. 
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3.2 CYP2W1 Membrane Topology and Search for Electron Partners 
(Paper III) 
 
As discussed in Introduction, cytochrome P450s are heme-containing monooxygenases 
which catalyze the oxidative reaction by incorporating one oxygen atom into substrates 
while the other oxygen atom is reduced to water. Such process is enabled by the 
electron transport chain in the cytosol, which consists of NADPH and cytochrome P450 
reductase (POR), and in some cases NADH, cytochrome b5 reductase and cytochrome 
b5. The P450s tether to the membrane of endoplasmic reticulum with the N-terminal 
signal anchor peptide, while the major bulk of heme-containing domain faces the 
cytosol (Figure 2). 
 
Previous studies have detected CYP2W1 enzyme by immunoblotting in colon cancer 
tissues and transfected HEK293 cells, demonstrating two separated immunoreactive 
bands, which implies the possibility of post-translational modification on CYP2W1 
protein. Further investigation identified the extra upper immunoreactive band as the 
consequence of glycosylation at the amino acid residue Asn177 of the enzyme (Gomez 
et al., 2010). The treatment by deglycosylating enzymes along with the membrane 
solubilizing reagent results in the depletion of the upper band in microsomes from 
transfected HEK293 cells, indicating that CYP2W1 enzyme is mostly likely embedded 
in the lumen of ER adopting atypical membrane topology, which is in line with the 
luminal residing glycosylation machinery. However, such luminal orientation is 
counterintuitive to the nature of monooxygenases which requires interaction with the 
redox partners residing on the cytosolic side of the ER membrane. CYP2W1 has indeed 
shown very potent catalytic activity towards a series of duocarmycin analogues both in 
vitro and in vivo (Travica et al., 2013). In order to address this fundamental question, 
there are two possible hypotheses: I. CYP2W1 is not completely luminally oriented, 
and partially remains in the ordinary membrane topology facing cytosol, which 
explains the functional activity; II. CYP2W1 is completely inverted but there is an 
alternative reducing partner equivalent to POR or cytochrome b5 in the ER lumen that 
contributes electrons to CYP2W1. 
 
With regard to the first hypothesis, we have applied various experimental approaches 
including the traditional protease protection assay and a novel redox-sensitive 
luciferase assay to investigate CYP2W1’s membrane topology. As mentioned 
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previously, the protease protection assay cannot determine whether the whole pool of 
CYP2W1 has inverted topology or not. Therefore, we introduced a luciferase reporter 
assay approach based on the redox sensitive luciferase (Gluc) from Gaussia princeps 
and a tandem green fluorescence protein (GFP) that are fused to the C-terminus of 
CYP2W1. The rationale is that Gluc luciferase requires the oxidative environment in 
the ER lumen to fold properly, emitting the luminescence signal at least ten folds 
higher than in cytosol, thus allowing to discriminate between the luminal and cytosolic 
localization of the protein in question (Li et al., 2012). The GFP is used to normalize 
the expression level of the fusion protein. The CYP2W1 fusion construct (2W1-GG) as 
well as the cytosolic (GG-cyto) and luminal (GG-ER) controls together with the 
CYP2C8 recombinant construct (2C8-GG) were transfected to HEK293 cells and 
analyzed in parallel. The result revealed that the tested constructs fall into two distinct 
groups according to the ratios of luminescence/fluorescence signals: the constructs 
2W1-GG and GG-ER belonged to one group that has very high bioluminescence signal 
compared to the other group consisting of 2C8-GG and GG-cyto. These data confirmed 
the canonical cytosolic topology of CYP2C8 and moreover indicated the completely 
luminal orientation of CYP2W1. The protease protection assay verified such topology 
by showing the luminal residence of the C-terminal of CYP2W1 utilizing a C-terminus 
FLAG tagged CYP2W1 construct.  
 
Figure 6. The redox sensitive luciferase reporter assay indicates the completely luminal 
orientation of CYP2W1. SP: signal peptide; KDEL: C-terminal ER-retention signal. 
The inverted topology of CYP2W1 challenges the postulate of the electron transport 
chain of P450s that involves redox partners POR and cytochrome b5 facing cytosol. We 
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investigated whether POR is the electron donor of CYP2W1 by inhibiting the 
expression of POR using siRNA in stably transfected HEK293 cells. The results shown 
in Figure 7 clearly demonstrated the efficient knockdown of POR. Under such 
circumstances, the CYP2W1 in intact HEK293 cells maintained its robust catalytic 
activity towards specific substrate ICT2726 while CYP2C8 enzyme catalysis was 
substantially affected by the absence of POR. Identical results were found when DPI, 
an efficient POR inhibitor (McGuire et al., 1998), was added to the system. These data 
solidly proved that POR is not interacting with CYP2W1. Similar scenario was seen 
when PTU was employed to inhibit flavin reductases including cytochrome b5 
reductase (Lee and Kariya, 1986). Taken together these data indicate that CYP2W1 
catalytic activity is not dependent on the presence of either POR or cytochrome b5 
reductase, suggesting other redox partner(s) in the lumen that may interact with 
CYP2W1. 
 
Figure 7. P450 reductase (POR) is not the electron donor to CYP2W1. 
 
Interestingly, glycosylation has been found to be relevant for catalytic activity of 
CYP2W1 enzyme. The Asn177Ala (N177A) nonglycosylated mutant construct 
described previously (Gomez et al., 2010) was expressed in HEK293 cells and 
immunoblotting confirmed the complete absence of the glycosylation fraction. 
Catalytic activity characterization of the nonglycosylated mutant towards ICT2726 
revealed significantly reduced metabolite formation when compared to the 
corresponding wild type CYP2W1 construct. 
 
In summary, our findings strongly support the completely inverted topology of 
CYP2W1 facing ER lumen, and exclude canonical redox partners as electron suppliers 
to CYP2W1. This suggests the existence of the hypothetical luminal electron donor(s) 
that remain to be identified.  
 
ERp29
HEK-2W1 HEK-2C8
POR
*
CYP2W1 CYP2C8
si
C
on
tr
ol
si
P
O
R
 5
0n
M
si
P
O
R
 1
00
nM
0
20
40
60
80
100
120
re
la
ti
v
e
 c
a
ta
ly
ti
c
 a
c
ti
v
iy
si
C
on
tr
ol
si
P
O
R
 5
0n
M
si
P
O
R
 1
00
nM
0
20
40
60
80
100
120
*
**
re
la
ti
v
e
 c
a
ta
ly
ti
c
 a
c
ti
v
iy
 26 
3.3 CYP2W1 in the Development 
 
3.3.1 Developmental expression of CYP2W1 (Paper II) 
 
The CYP2W1 gene is evolutionary conserved with transcripts reported in rat fetal colon 
and in mouse embryonic pooled tissues (Karlgren et al., 2006, Choudhary et al., 2005), 
whereas expression is silenced in adult life. Previous study has elucidated that 
epigenetic modification underlines the tumor-specific expression of CYP2W1, in which 
the demethylation of the CpG island located in the exon1/intron 1 junction of CYP2W1 
gene results in activated transcription in colorectal tumors (Gomez et al., 2007). The 
expression pattern of CYP2W1 is reminiscent of a group of oncofetal genes, which are 
regulated by similar mechanisms during fetal development and carcinogenesis. 
 
Previous reports of CYP2W1 expression in rat or murine fetal tissue were limited to the 
transcriptional level and the human fetal tissue expression data was not available. In the 
current study we analyzed the Cyp2w1 mRNA and protein expression levels in murine 
colon and small intestine tissues at several time points ranging from embryonic days 13 
(E13) until adulthood. As shown in Figure 8. Cyp2w1 reached significant expression 
levels during fetal stages both in colon and small intestine with the peak level at E18 
and then decreased drastically after birth until becoming undetectable at four weeks of 
age. However, there were slight differences in expression curves between the small 
intestine and colon: Cyp2w1 is expressed earlier in fetal small intestine and also 
diminished earlier at around postnatal day three (PND 3) while Cyp2w1 mRNA in 
colon tended to be more stable until PND 7. Western blot confirmed the protein 
expression of Cyp2w1 that shared the same pattern as mRNA in colon and small 
intestine. It is worth to mention that liver samples from different developmental stages 
were analyzed as well and we did not detect any Cyp2w1 transcripts at any time point. 
 
Regarding to the CYP2W1 expression in human fetal colon and small intestine, 
samples from gestational weeks 18-19 were analyzed along with a few adult samples at 
various ages. As we expected, significant CYP2W1 expression was found in colon and 
small intestine during fetal stages and not detected at any adult ages, which is consistent 
with the murine data. 
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Figure 8. The developmental curve of Cyp2w1 mRNA expression in murine small 
intestine and colon. 
 
It was also of interest to identify the cell types in fetal gut expressing CYP2W1. In the 
current study, immunohistochemical analysis using two CYP2W1 antibodies was 
carried out on the human fetal colon at gestational week 19. CYP2W1 signals were 
observed exclusively in the crypt cells lining the epithelium layer, co-localizing with 
the ER marker, GRP78, while the other layers including lamina propria, muscularis 
mucosa or submucosa have no CYP2W1 staining, as shown in Figure 9. 
 
Figure 9. CYP2W1 expression in human fetal colon at gestational week 19. M852: 
human CYP2W1 in-house antibody; GRP78: endoplasmic reticulum marker. 
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3.3.2 Regulation of CYP2W1 (Paper II) 
 
As reported previously, DNA demethylation of CpG island in exon 1/intron 1 junction 
triggers the expression of CYP2W1 in colon tumor tissue. We tested whether such 
mechanism is involved in the regulation of CYP2W1 expression in fetal gut. The 
methylation level of the exon 1/intron 1 region of human CYP2W1 gene was compared 
between the fetal and postnatal colon tissue. The results revealed that six CpG sites 
within this region have higher methylation level in adult samples than in fetal tissues 
indicating the involvement of epigenetics in regulating the developmentally specific 
expression of CYP2W1, which is in consistent with the findings in colon cancers. The 
methylation states in murine pre- and postnatal colon samples showed significant 
correlation between Cyp2w1 mRNA expression and DNA methylation percentage in 
six analyzed areas of high CpG density sites. 
 
CYP2W1 has significant expression levels in colon cancer but is not detectable in 
normal tissues, rendering it an attractive target for colon cancer therapy utilizing the 
prodrug monotherapy (PMT) concept (de Groot et al., 2001, Denny, 2004). When 
applying the PMT to colon cancer, it is beneficial to up-regulate CYP2W1 expression 
to obtain more significant outcome. In this study, we were able to identify a colon 
cancer cell line HCC2998 that endogenously expresses considerable amount of 
catalytically active CYP2W1. Utilizing the HCC2998 cell model for screening the 
potential inducers of CYP2W1, we found significant inducing effect on CYP2W1 
mRNA levels when the cells were treated with imatinib, linoleic acid and its two 
conjugated forms. Imatinib is a tyrosine-kinase inhibitor used in the treatment of 
multiple cancers (Druker et al., 2006, van Oosterom et al., 2001), and its potent effect 
on CYP2W1 expression might open up a possibility of a neoadjuvant colon cancer 
therapy prior to the administration of prodrugs specifically activated by CYP2W1 to 
cytotoxins. 
 
Collectively, in this study we have described a detailed developmental curve of 
CYP2W1 expression in mice and human gut tissues, revealed that the fetal specific 
expression is largely modulated by epigenetic regulation and found potential 
transcriptional inducers of CYP2W1. 
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3.3.3 Endogenous role of CYP2W1 in gut development (Paper IV, 
manuscript) 
 
Since the first identification of a partial sequence from HepG2 cDNA library in 2000, 
several aspects of CYP2W1 have been investigated including substrate specificity, 
genetic polymorphism, epigenetic regulation, and most importantly, the tumor-specific 
expression, which promotes it as a promising target for the treatment of colon primary 
tumors and hepatic metastases. Despite the promising role of CYP2W1 in the context 
of colon cancer therapy, little is known however regarding its endogenous function, 
leaving it so far in the ranks of orphan enzymes. 
 
Previously characterized expression pattern of CYP2W1 shares common features with 
the expression of oncofetal genes. The CYP2W1 gene is evolutionarily conserved 
among various vertebrate species, and has very confined expression in the epithelium 
of the fetal gastrointestinal tract. It was postulated that CYP2W1 may have potential 
role during gut development. 
 
In order to understand the endogenous function of CYP2W1, a mouse model was 
established with the genomic depletion of the enzyme. qPCR analysis of Cyp2w1 
mRNA from fetal colon and small intestine validated the successful abolishment of the 
gene in such knockout mice. The gastrointestinal phenotype of the adult Cyp2w1 null 
mouse was investigated in comparison with the corresponding wild type littermates. As 
shown in Figure 10, we found that the crypt length of the distal colon in KO mice is 
significantly smaller than that in the WT mice, which appeared as a thinner epithelium 
layer by H&E staining. Such a phenotype was not shown in any other parts of the GI 
tract including proximal colon, duodenum, jejunum, and ileum. 
 
Next, we aimed to explore the molecular mechanisms that are associated with such 
phenotypic alteration. The transcript profiling of the distal colon from adult WT and 
KO mice was accomplished by microarray analysis and over hundred genes were found 
to be differentially expressed. The pathway analysis identified that a number of down-
regulated genes in KO mice colon were involved in the cell adhesion and extracellular 
matrix establishment. The genes with the most significantly reduced expression were 
selected including Myl9, Fn1, Flna, and Itga5 for qPCR validation. Apart from the 
adult colon samples, fetal colon tissues at E13 and E18 were included as well. The 
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mRNA levels of analyzed genes were significantly decreased in adult Cyp2w1 null 
mice distal colon compared to WT, confirming thus the transcriptomics data. With 
respect to the fetal expression levels of these four genes, there was no difference at E13, 
however, a decreasing expression tendency was observed at E18 in KO mice colon 
samples. The results indicated that the depletion of the fetal Cyp2w1 expression has an 
impact on the adult expression of these genes, however, the mechanisms are yet to be 
explored. Recent studies demonstrated CYP2W1’s capability of catalyzing a variety of 
endogenous lipid molecules, in particular very high affinity were reported towards the 
retinoic acid (Zhao et al., 2016b, Xiao and Guengerich, 2012), which might be 
important in regulating the expression of the downstream genes in the gut tissues. 
 
 
Figure 10. The crypt length of distal colon is significantly decreased in three months 
old Cyp2w1 knockout mice (KO) as compared to the wild type littermates (WT). 
 
In summary, we have discovered the phenomenon of the decreased crypt length and 
revealed down-regulation of a number of cell adhesion genes in the Cyp2w1 KO 
mouse, providing thus more insights into a hypothetic endogenous function of 
CYP2W1 in the gut development. 
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4 SUMMARY 
 
 
This thesis can be summarized as follows: 
 
 The polymorphic CYP2W1 gene variants are not related to the risk for 
colorectal cancer, which is in line with their equal functionality in metabolizing 
the specific substrates including anti-cancer prodrugs. 
 
 CYP2W1 enzyme has a completely inverted membrane topology as compared 
to other P450s. Neither P450 reductase nor cytochrome b5 reductase are 
involved in the electron transfer to CYP2W1. The nonglycosylated mutant has 
reduced catalytic activity compared to the wild type enzyme. 
 
 CYP2W1 is expressed in the course of mouse and human embryonic gut 
development, and is silenced shortly after birth by DNA methylation. The 
enzyme localization is restricted to the crypt cells. Antitumor agent imatinib can 
induce CYP2W1 expression in colon carcinoma cell line HCC2998. 
 
 The depletion of Cyp2w1 gene expression leads to the decreased crypt length of 
distal colon in adult mice, and is correlated with down regulation of a number 
of genes involved in cell adhesion. 
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5 FUTURE PERSPECTIVES  
 
The establishment of the full sequence map of the human genome strongly 
contributed to the discoveries of many new genes including cytochrome P450 2W1. 
The initial characterization revealed tumor specific expression profile of the enzyme, 
which immediately caught our attention and suggested a novel cancer treatment 
approach by targeting CYP2W1 using the prodrug strategy. The success in synthesis 
of CYP2W1 specific substrates duocarmycin analogues and their promising tumor-
inhibitory effect in in vivo colon tumor xenografts pushes this strategy further towards 
the clinical setting. The equal capacity of different CYP2W1 polymorphic variants in 
prodrug catalysis circumvents the need of screening the CYP2W1 genotype in CRC 
patients. Elevated CYP2W1 expression is found in colon cancer metastases, our 
ongoing studies are dedicated to the analysis of the functional activity of CYP2W1 in 
the metastatic tissues and generation of a novel xenograft mouse model using liver 
metastatic tissue from CRC patients, in order to estimate the tumor-killing efficacy of 
duocarmycin prodrugs. In addition, we plan to study the mechanisms of metastatic 
dissemination investigating the effects of co-culture of a panel of colon cancer cells 
with the 3D spheroids of primary human hepatocytes. 
  
The oncofetal expression pattern of CYP2W1 is governed by epigenetic mechanisms. 
DNA methylation of CYP2W1 gene leads to the expression silencing in adult tissues. 
The significant expression of CYP2W1 enzyme in course of the fetal gut 
development implies the potential endogenous role in embryogenesis. Indeed, the 
Cyp2w1 knockout mice revealed a phenotype of shortened crypt length in distal colon 
at adulthood, along with decreased expression of a number of cell adhesion proteins. 
Interestingly, this was not observed during fetal life when the translation of Cyp2w1 
gene occurs, although a tendency of down-regulation in cell adhesion genes was 
noticed. One possible explanation would be the long-lasting alterations in DNA 
methylation of the regulatory genes. Therefore, it would be interesting to investigate 
the epigenetic profiling of those down-regulated genes to characterize the regulatory 
elements or signaling pathways which might be associated with fetal CYP2W1 
expression.  
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The recently reported high affinity binding constants of retinoids toward CYP2W1 
implicates the potential involvement of the enzyme both in fetal development and in 
cancer progression. Retinoids are critical in regulating cell proliferation, 
differentiation, neuron development in the early embryogenesis. Moreover, retinoid 
signaling is shown to be undermined during tumor progression and retinoids are used 
in cancer therapy for proliferation arrest and differentiation induction (Tang and 
Gudas, 2011). Members of the CYP26 family are the major enzymes that metabolize 
retinoids into the less bioactive products. High levels of CYP26A1 are observed in 
several cancer types (Mongan and Gudas, 2007). With respect to the important role of 
retinoids in development and carcinogenesis, it is imperative to validate CYP2W1 
mediated retinoid catalysis both in embryonic and in tumor tissues.  
 
CYP2W1 has inverted membrane topology with the functional domain orienting 
toward ER lumen, which disables the redox interaction with canonical cytosol-facing 
CYP reductases. However, robust catalytic activity towards duocarmycin analogues 
has been shown in intact cells and in mice xenografts, indicating the existence of an 
ER luminal redox partner. Further investigations should identify the direct electron 
donor by means of RNA interfering or chemical inhibitors of luminal reductases, thus 
providing the additional opportunity of enhancing CYP2W1 catalytic activity via 
manipulation of its redox partner in cancer tissues. 
 
In summary, the oncofetal CYP2W1 gene exhibits a temporal and spatial expression 
pattern and unique membrane topology. Future research may provide us with a 
clearer picture of CYP2W1 physiological function as well as with novel approaches 
for targeted cancer therapy. 
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